全文获取类型
收费全文 | 657篇 |
免费 | 77篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 53篇 |
妇产科学 | 9篇 |
基础医学 | 96篇 |
口腔科学 | 9篇 |
临床医学 | 70篇 |
内科学 | 229篇 |
皮肤病学 | 1篇 |
神经病学 | 18篇 |
特种医学 | 6篇 |
外科学 | 89篇 |
综合类 | 7篇 |
预防医学 | 27篇 |
眼科学 | 7篇 |
药学 | 34篇 |
肿瘤学 | 77篇 |
出版年
2023年 | 6篇 |
2022年 | 12篇 |
2021年 | 12篇 |
2020年 | 16篇 |
2019年 | 19篇 |
2018年 | 27篇 |
2017年 | 14篇 |
2016年 | 21篇 |
2015年 | 28篇 |
2014年 | 28篇 |
2013年 | 27篇 |
2012年 | 23篇 |
2011年 | 30篇 |
2010年 | 28篇 |
2009年 | 14篇 |
2008年 | 30篇 |
2007年 | 30篇 |
2006年 | 33篇 |
2005年 | 20篇 |
2004年 | 29篇 |
2003年 | 18篇 |
2002年 | 31篇 |
2001年 | 27篇 |
2000年 | 21篇 |
1999年 | 23篇 |
1998年 | 9篇 |
1997年 | 5篇 |
1996年 | 8篇 |
1995年 | 6篇 |
1994年 | 8篇 |
1993年 | 12篇 |
1992年 | 16篇 |
1991年 | 10篇 |
1990年 | 6篇 |
1989年 | 8篇 |
1988年 | 5篇 |
1987年 | 6篇 |
1986年 | 6篇 |
1985年 | 6篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1982年 | 2篇 |
1980年 | 5篇 |
1969年 | 2篇 |
1939年 | 3篇 |
1938年 | 2篇 |
1932年 | 2篇 |
1913年 | 2篇 |
1912年 | 2篇 |
1898年 | 2篇 |
排序方式: 共有734条查询结果,搜索用时 31 毫秒
31.
Claudia Elsner Alessandro D'Ausilio Gustaf Gredebäck Terje Falck-Ytter Luciano Fadiga 《Neuropsychologia》2013,51(3):488-492
We examined the hypothesis that predictive gaze during observation of other people's actions depends on the activation of corresponding action plans in the observer. Using transcranial magnetic stimulation and eye-tracking technology we found that stimulation of the motor hand area, but not of the leg area, slowed gaze predictive behavior (compared to no TMS). This result shows that predictive eye movements to others' action goals depend on a somatotopical recruitment of the observer's motor system. The study provides direct support for the view that a direct matching process implemented in the mirror-neuron system plays a functional role for real-time goal prediction. 相似文献
32.
Ebba Norsted Gregory Ada Delaney Sally AbdelMoaty Duygu B. Bas Simone Codeluppi Gustaf Wigerblad Camilla I. Svensson 《Journal of neuroscience research》2013,91(2):300-312
Astrocyte activation is an important feature in many disorders of the central nervous system, including chronic pain conditions. Activation of astrocytes is characterized by a change in morphology, including hypertrophy and increased size of processes, proliferation, and an increased production of proinflammatory mediators. The xanthine derivatives pentoxifylline and propentofylline are commonly used experimentally as glial inhibitors. These compounds are generally believed to attenuate glial activity by raising cyclic AMP (cAMP) levels and inhibiting glial tumor necrosis factor (TNF) production. In the present study, we show that these substances inhibit TNF and serum‐induced astrocyte proliferation and signaling through the mammalian target of rapamycin (mTOR) pathway, demonstrated by decreased levels of phosphorylated S6 kinase (S6K), commonly used as a marker of mTOR complex (mTORC) activation. Furthermore, we show that pentoxifylline and propentofylline also inhibit JNK and p38, but not ERK, activation induced by TNF. In addition, the JNK antagonist SP600125, but not the p38 inhibitor SB203580, prevents TNF‐induced activation of S6 kinase, suggesting that pentoxifylline and propentofylline may regulate mTORC activity in spinal astrocytes partially through inhibition of the JNK pathway. Our results suggest that pentoxifylline and propentofylline inhibit astrocyte activity in a broad fashion by attenuating flux through specific pathways. © 2012 Wiley Periodicals, Inc. 相似文献
33.
34.
Charlotte Gran Junfeng Wang Hareth Nahi Linda Koster Gösta Gahrton Herman Einsele Riitta Niittyvoupio Matthias Edinger Dietrich Beelen Fabio Ciceri Martin Bornhäuser Jürgen Finke Liesbeth C. de Wreede Per Ljungman Stephan Mielke Johanna Tischer Laurent Garderet Stefan Schönland Ibrahim Yakoub-Agha Nicolaus Kröger 《British journal of haematology》2020,189(5):e213-e217
35.
36.
Maja Jahnmatz Margaretha Ljungman Eva Netterlid Maria C. Jenmalm Lennart Nilsson Rigmor Thorstensson 《Clinical and Vaccine Immunology : CVI》2014,21(9):1301-1308
In order to impede the increase in pertussis incidence in the adolescent group, a school-leaving booster dose administered at the age of 14 to 16 years will be introduced in Sweden in 2016. Preceding this introduction, an open-label, randomized, multicenter, clinical trial without a control group and with blinded analysis was performed, investigating both safety and immunogenicity. Reported here are the memory B-cell and serological responses detected in a smaller cohort (n = 34) of the 230 subjects recruited to the study. All subjects had received primary vaccination consisting of three doses of diphtheria–tetanus–5-component pertussis (DTaP5) vaccine, at 3, 5, and 12 months of age, and a tetanus–low-dose diphtheria–5-component pertussis (Tdap5) vaccine booster at 5.5 years. In this study, the subjects were randomly assigned and received either a Tdap1 or Tdap5 booster. Of the 230 participants, 34 subjects had samples available for evaluation of IgG-producing memory B-cell responses. Both vaccine groups had significant increases in pertussis toxin-specific serum IgG levels, but only the 1-component group showed significant increases in pertussis toxin-specific memory B cells. The 5-component group had significant increases in filamentous hemagglutinin- and pertactin-specific memory B-cell and serum IgG levels; these were not seen in the 1-component group, as expected. In conclusion, this study shows that a 5th consecutive dose of an acellular pertussis vaccine induces B-cell responses in vaccinated adolescents. (This study has been registered at EudraCT under registration no. 2008-008195-13 and at ClinicalTrials.gov under registration no. NCT00870350.) 相似文献
37.
38.
39.
Monika Scheer Christian Vokuhl Iris Veit‐Friedrich Marc Münter Thekla von Kalle Michael Greulich Steffan Loff Sabine Stegmaier Monika Sparber‐Sauer Felix Niggli Ruth Ladenstein Bernarda Kazanowska Gustaf Ljungman Kirsi Jahnukainen Jrg Fuchs Stefan S. Bielack Ewa Koscielniak Thomas Klingebiel 《Pediatric blood & cancer》2020,67(2)
40.
Vladimir Lj Lazarevic Myriam Labopin Wu Depei Ibrahim Yakoub‐Agha Anne Huynh Per Ljungman Nicolaas Schaap Jan J. Cornelissen Natacha Maillard Pietro Pioltelli Tobias Gedde‐Dahl Stig Lenhoff Mohamed Houhou Jordi Esteve Mohamad Mohty Arnon Nagler 《American journal of hematology》2018,93(1):31-39
The aim of the study was to assess the role of allogeneic stem cell transplantation (SCT) in patients diagnosed with BCR‐ABL1‐positive acute myeloid leukemia (AML). Fifty‐seven patients (median age, 48 years, range: 19‐67) with BCR‐ABL1 positive AML undergoing SCT were identified. The majority of the patients (70%) received a TKI before the transplant. At SCT 48 patients were in CR (45 in CR1), while 9 patients were transplanted in a more advanced stage of the disease. MRD was negative (BCR‐ABL1/ABL < 104) at time of SCT in 36.1% (14/40). After SCT, 16 (61.5%) out of 26 patients with MRD positive at transplantation reached MRD negativity. After a median follow‐up of 6.3 years (0.7–14.2), NRM, RI, LFS, OS, and GRFS at 5 years were 18.1%, 37%, 44.2%, 53.8%, and 32.1%, respectively. The cumulative incidence of acute GvHD grade II‐IV was 16.4%, incidence of chronic GvHD 24.9%, and of extensive cGvHD 21.4%, respectively. In patients who received SCT in CR1, 5‐yr NRM, RI, LFS, OS, and GRFS were 15.9%, 36.4%, 46.5%, 59.4%, and 34.9%, respectively. Univariate analysis showed that age (<50 vs. ≥50 years) was associated with RI (5‐yr: 22.7 vs. 50%), LFS (5‐yr: 61.9 vs. 31.8%), and GRFS (5‐yr: 52.4 vs. 18.2%), whereas MRD‐negative status before SCT was associated with an improved GRFS (38.9 vs. 16.7%). We conclude that the outcome of patients <50 years of age with BCR‐ABL1‐positive AML receiving allogeneic SCT in CR is relatively favorable, possibly reflecting the beneficial effect of the use of TKI. 相似文献